IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 398.00, up by 2.60 points or 0.66% from its previous closing of Rs. 395.40 on the BSE.

The scrip opened at Rs. 396.60 and has touched a high and low of Rs. 403.00 and Rs. 392.65 respectively. So far 21781 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 403.00 and Rs. 386.20 respectively. The current market cap of the company is Rs. 11219.01 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.73% and 18.63% respectively.

Glenmark Pharmaceuticals has become the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

Teneligliptin is a widely used DPP4i (Dipeptidyl Peptidase 4) inhibitor whereas Dapagliflozin is the most prescribed SGLT?2i (Sodium glucose co?transporter 2) inhibitorfor diabetic patientsin the country.  While Zita D is a promising treatment option in managing uncontrolled Type 2 diabetes with co?morbidities, this FDC has also proven to be effective among adult diabetic patients without comorbidities. Glenmark’s Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg, per day.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.